#GivingTuesday is November 27th, and we need you to help us make a big impact! Please join us in #GivingTeal, for the 22,000 American women diagnosed with ovarian cancer every year, and the 200,000 living with this disease. Here’s how you can help. Facebook Fundraisers On November 27th, Facebook will match donations up to $7 … Continued
(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA. More specifically, they found evidence that ovarian cancer cells formed in the fallopian tube change how the … Continued
(October 18, 2018) Longtime OCRA Scientific Advisory Committee member and former grantee Kunle Odunsi, MD, PhD, has been elected to the National Academy of Medicine—a distinguished lifetime designation that is considered one of the highest honors in health and medicine. Members are elected by their peers based on their contributions to the advancement of the … Continued
(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer. Using ovarian tumors from humans and mice, they found that T cells, vital to destroying cancerous cells, are inhibited because of the tumor’s effect … Continued
(October 2, 2018) A study by the Mayo Clinic earlier this year aimed to increase the amount of genetic counseling referrals to epithelial ovarian cancer patients by supplying patients with a Genetics Referral Toolkit. The research was funded by OCRA through the SU2C Ovarian Cancer Dream Team. The toolkit included a checklist, a way to … Continued
(October 1, 2018) We’re shortening our name, to make it easier to say and easier to write. OCRFA is now Ovarian Cancer Research Alliance (OCRA). You can find us at ocrahope.org, and on social media at @OCRAHOPE.
(September 21, 2018) In an international collaboration funded in part by OCRFA, published recently in Cell, researchers used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in patients with high grade serous ovarian cancer. The biomarker, known as CT45, is associated with better response to chemotherapy and … Continued
We need your help this September. Ovarian cancer is the fifth leading cause of cancer death among women, and is the deadliest of gynecologic cancers. #ResearchMatters. Research is the key to defeating this devastating disease. That’s why every day, OCRFA-funded scientists are working to find new ways to prevent ovarian cancer, developing better methods to … Continued
Be a voice for the ovarian cancer community. Update: The deadline to apply for our 2019 Advocate Leader program has now passed. (August 28, 2018) Registration is now open for our 2019 Advocate Leader program. Apply today to join our diverse community of survivors, caregivers and activists from across the country using their voices to effect … Continued
(June 6, 2018) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, and to organizational transparency and accountability, as we continue to strive toward a cure for … Continued
(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued
(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued
Get email updates about research news, action alerts, and ways to join the fight.
